[肝细胞癌在阿特唑单抗和贝伐单抗联合治疗后发生自身免疫性溶血性贫血，改善后过渡到二线治疗：1例报告]。

Q4 Medicine

Japanese Journal of Gastroenterology Pub Date : 2025-01-01 DOI:10.11405/nisshoshi.122.138

Masayoshi Ko, Kota Fujimaki, Shohei Igarashi, Takato Maeda, Koji Shimaya, Norihiro Hanabata, Kosuke Kanazawa, Hiroshi Numao, Masaki Munakata

{"title":"[肝细胞癌在阿特唑单抗和贝伐单抗联合治疗后发生自身免疫性溶血性贫血，改善后过渡到二线治疗：1例报告]。","authors":"Masayoshi Ko, Kota Fujimaki, Shohei Igarashi, Takato Maeda, Koji Shimaya, Norihiro Hanabata, Kosuke Kanazawa, Hiroshi Numao, Masaki Munakata","doi":"10.11405/nisshoshi.122.138","DOIUrl":null,"url":null,"abstract":"Atezolizumab and bevacizumab combination therapy was initiated in a 71-year-old female patient with unresectable hepatocellular carcinoma. Severe anemia, which was managed with blood transfusion and demonstrated improvement, was observed after the treatment. However, anemia subsequently reoccurred, accompanied by signs of hemolysis. The condition was diagnosed as autoimmune hemolytic anemia due to atezolizumab. Steroid therapy exhibited improvement, and second-line treatment with lenvatinib was successfully initiated. The possibility of autoimmune hemolytic anemia should be considered when anemia is observed during immunotherapy for hepatocellular carcinoma.","PeriodicalId":35808,"journal":{"name":"Japanese Journal of Gastroenterology","volume":"122 2","pages":"138-147"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Hepatocellular carcinoma developing autoimmune hemolytic anemia after atezolizumab and bevacizumab combination therapy, transitioning to second-line treatment following improvement:a case report].\",\"authors\":\"Masayoshi Ko, Kota Fujimaki, Shohei Igarashi, Takato Maeda, Koji Shimaya, Norihiro Hanabata, Kosuke Kanazawa, Hiroshi Numao, Masaki Munakata\",\"doi\":\"10.11405/nisshoshi.122.138\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Atezolizumab and bevacizumab combination therapy was initiated in a 71-year-old female patient with unresectable hepatocellular carcinoma. Severe anemia, which was managed with blood transfusion and demonstrated improvement, was observed after the treatment. However, anemia subsequently reoccurred, accompanied by signs of hemolysis. The condition was diagnosed as autoimmune hemolytic anemia due to atezolizumab. Steroid therapy exhibited improvement, and second-line treatment with lenvatinib was successfully initiated. The possibility of autoimmune hemolytic anemia should be considered when anemia is observed during immunotherapy for hepatocellular carcinoma.\",\"PeriodicalId\":35808,\"journal\":{\"name\":\"Japanese Journal of Gastroenterology\",\"volume\":\"122 2\",\"pages\":\"138-147\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Japanese Journal of Gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.11405/nisshoshi.122.138\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11405/nisshoshi.122.138","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

阿特唑单抗和贝伐单抗联合治疗开始于一个71岁的女性患者不可切除的肝细胞癌。治疗后观察到严重的贫血，输血治疗后表现出改善。然而，贫血随后再次发生，并伴有溶血迹象。由于atezolizumab，诊断为自身免疫性溶血性贫血。类固醇治疗表现出改善，lenvatinib二线治疗成功启动。在肝细胞癌的免疫治疗中观察到贫血时，应考虑自身免疫性溶血性贫血的可能性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

[Hepatocellular carcinoma developing autoimmune hemolytic anemia after atezolizumab and bevacizumab combination therapy, transitioning to second-line treatment following improvement:a case report].

Atezolizumab and bevacizumab combination therapy was initiated in a 71-year-old female patient with unresectable hepatocellular carcinoma. Severe anemia, which was managed with blood transfusion and demonstrated improvement, was observed after the treatment. However, anemia subsequently reoccurred, accompanied by signs of hemolysis. The condition was diagnosed as autoimmune hemolytic anemia due to atezolizumab. Steroid therapy exhibited improvement, and second-line treatment with lenvatinib was successfully initiated. The possibility of autoimmune hemolytic anemia should be considered when anemia is observed during immunotherapy for hepatocellular carcinoma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Japanese Journal of Gastroenterology Medicine-Gastroenterology

CiteScore

0.20

自引率

0.00%

发文量

期刊介绍： The Journal of Gastroenterology, which is the official publication of the Japanese Society of Gastroenterology, publishes Original Articles (Alimentary Tract/Liver, Pancreas, and Biliary Tract), Review Articles, Letters to the Editors and other articles on all aspects of the field of gastroenterology. Significant contributions relating to basic research, theory, and practice are welcomed. These publications are designed to disseminate knowledge in this field to a worldwide audience, and accordingly, its editorial board has an international membership.